董事会认为，该减少乃主要由于：(i)生物降解购物袋及生物降解农产品袋卷销售额下降等因素导致本期 间收入减少而导致毛利下降;(ii)本期间研发开支减少两项因素的综合影响。 智通财经APP讯，中宝新材(02439)发布公告，集团预期截至2025年6月30日止六个月取得归属于公司股 权持有人的净利润将较截至2024年6月30日止六个月约人民币4780万元减少至不超过人民币3800万元。 ...

Core Viewpoint - Zhongbao New Materials (02439) expects a decrease in net profit attributable to equity holders for the six months ending June 30, 2025, to not exceed RMB 38 million, down from approximately RMB 47.8 million for the six months ending June 30, 2024 [1] Group 1 - The decrease in net profit is primarily attributed to a decline in sales of biodegradable shopping bags and biodegradable agricultural product bag rolls, leading to reduced revenue and gross profit [1] - The company also noted a reduction in research and development expenses as a contributing factor to the profit decline [1]

中寶新材集團有限公 司 （於開曼群島註冊成立的有限公司） （股份代號：2439） 盈利警告 截至2025年6月30日止六個月 盈利減少 本公告乃中寶新材集團有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董事」） 會（「董事會」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)條及香 港法例第571章證券及期貨條例第XIVA部下之內幕消息條文（定義見上市規則）而作出。 香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Treasures New Materials Group Ltd. 本公司股東及潛在投資者於買賣本公司證券時務請審慎行事。 代表董事會 中寶新材集團有限公司 主席兼執行董事 張玉秋 董事會謹此知會本公司股東（「股東」）及潛在投資者，根據對董事會目前可得的最新資料 及本集團截至2025年6月30日止年度（「期間」）的未經審核簡明綜合管理賬目作出的初步審 閱及評估，本集團預期期間 ...

[Supplemental Announcement to the 2024 Annual Report](index=1&type=section&id=Supplemental%20Announcement%20Regarding%20the%20Annual%20Report%20for%20the%20Year%20Ended%20December%2031%2C%202024) This announcement provides supplementary details to the 2024 Annual Report, focusing on the share option scheme and board composition [Supplemental Details of Share Option Scheme](index=1&type=section&id=Supplemental%20Details%20of%20Share%20Option%20Scheme) This section details the specific terms, conditions, and procedures of the company's share option scheme, including offer, exercise, and validity [Consideration Payable and Offer Period for Share Options](index=1&type=section&id=%28H%29%20Consideration%20Payable%20and%20Offer%20Period%20for%20Share%20Options) - Eligible persons may accept the offer of granted share options within **28 days** from the offer date[2](index=2&type=chunk) - The consideration for share options is a non-refundable remittance of **HK$1.0**[2](index=2&type=chunk) - Offers not accepted by the acceptance date will be deemed irrevocably rejected[2](index=2&type=chunk) [Share Option Exercise Conditions and Procedures](index=2&type=section&id=Share%20Option%20Exercise%20Conditions%20and%20Procedures) - Share options must be exercised by the grantee via written notice to the company within the option period, specifying the number of shares to be exercised[3](index=3&type=chunk) - Each exercise notice must be accompanied by the full remittance of the total subscription price for the shares involved[3](index=3&type=chunk) - The exercise of share options may be subject to a vesting schedule determined at the sole discretion of the Board[4](index=4&type=chunk) - In case of grantee's death or permanent disability, their legal representative may exercise unexercised options within **12 months** of death/disability[4](index=4&type=chunk) - Upon termination of employment (except in specific cases), unexercised options will lapse unless otherwise decided by the Board[4](index=4&type=chunk) - In the event of a general offer or scheme of arrangement, grantees are entitled to exercise unexercised options within a specified period[4](index=4&type=chunk) - During corporate restructuring or merger, grantees may exercise all or part of their options within a specific period[6](index=6&type=chunk) - In case of voluntary liquidation, grantees may exercise options up to **two business days** before the shareholders' meeting[6](index=6&type=chunk) [Term of Share Option Scheme](index=3&type=section&id=%28J%29%20Term%20of%20Share%20Option%20Scheme) - The share option scheme is valid for **10 years** from March 31, 2023[5](index=5&type=chunk) - The scheme will expire on March 30, 2033, with no further options granted or offered thereafter[5](index=5&type=chunk) - All options granted before expiry and unexercised at that time remain valid and exercisable under the scheme's terms[5](index=5&type=chunk) [Other Supplemental Information](index=4&type=section&id=Other%20Supplemental%20Information) This section confirms the supplementary nature of this announcement to the 2024 Annual Report and lists the Board of Directors as of the announcement date - The additional information above supplements the 2024 Annual Report and should be read in conjunction with it, without affecting other information contained therein[7](index=7&type=chunk) - The Board of Directors includes Executive Directors Ms. Zhang Yuqiu (Chairperson), Mr. Shan Yuzhu, Mr. Li Xiquan, Mr. Li Peng; and Independent Non-executive Directors Dr. Lai King Ran, Dr. Song Xiaofeng, Mr. Leung Tsz Wing[8](index=8&type=chunk)

格隆汇8月19日丨中宝新材(02439.HK)公布，公司将于2025年8月29日召开董事会会议，以（其中包括） 审议及通过集团截至2025年6月30日止六个月的中期业绩及其发布，以及宣派中期股息（如有）。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 China Treasures New Materials Group Ltd. 主席兼執行董事 張玉秋 謹啟 中寶新材集團有限公 司 中國吉林省長春，2025年8月19日 （於開曼群島註冊成立的有限公司） （股份代號：2439） 於本公告日期，執行董事為張玉秋女士、單玉柱先生、李溪泉先生及李鵬先生；獨立非執 行董事為賴景然博士、宋曉峰博士及梁子榮先生。 董事會會議日期 中寶新材集團有限公司（「本公司」，及其附屬公司「本集團」）董事（「董事」）會（「董事會」） 宣佈，董事會會議將於2025年8月29日（星期五）舉行，藉以（其中包括）審議通過本集團截 至2025年6月30日止六個月的中期業績及其公告以供發佈，以及考慮宣派中期股息（如有）。 代表董事會 中寶新材集團有限公司 ...

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中寶新材集團有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02439 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | | 增加 / 減少 (-) | | | 0 | | | | HKD | | 0 | | 本月底結存 | | | 10,000,000,000 | HKD | | 0.01 | HKD | | 100,000,000 | 本月 ...

Financial Performance - The company's revenue for the fiscal year 2024 increased by approximately 11.4% to around RMB 407.5 million, compared to RMB 365.8 million in fiscal year 2023[9]. - The profit attributable to shareholders reached approximately RMB 111.2 million, representing a significant year-on-year growth of about 32.4% from RMB 84.0 million in the previous fiscal year[9]. - The group achieved a net profit margin of 27.6% in FY2024, up from 23.1% in FY2023[25]. - The group recorded a profit of approximately RMB 112.4 million for the year, a growth of 32.9% compared to RMB 84.6 million in FY2023, attributed to increased revenue and other income[39]. - The cost of sales for the year was approximately RMB 245.5 million, an increase of about 11.4% from RMB 220.4 million in the previous year, primarily due to rising production and raw material costs[31]. - Gross profit for the year was approximately RMB 162.0 million, up about 11.3% from RMB 145.5 million, with a stable gross margin of approximately 39.8%[32]. - Other income rose significantly to approximately RMB 20.3 million, an increase of about 178.1% from RMB 7.3 million, mainly due to increased government subsidies and rental refunds[33]. - The total asset return increased to 16.3% in FY2024 from 15.2% in FY2023[25]. - The interest coverage ratio improved significantly to 41.1 times in FY2024, compared to 25.9 times in FY2023[25]. Production and Operations - The company has established two production bases in Dongguan, Guangdong Province, and Anji, Zhejiang Province, with the Dongguan factory fully operational in fiscal year 2024[10]. - The company plans to concentrate operations at its main production base in Changchun, Jilin Province, after ceasing operations at the Dongguan and Anji factories[10]. - Approximately HKD 59.2 million of the funds raised post-IPO have been allocated for expanding the new production line at the Changchun base and for R&D projects[11]. - The company has entered into a transfer agreement to purchase land in Changchun to establish a new production base aimed at increasing production capacity for biodegradable plastic products[9]. - The new production base in Changchun is still in the planning stage as of the report date[9]. - The group plans to consolidate operations by relocating machinery from Dongguan and Anji factories to the main base in Changchun, aiming for cost efficiency and improved production capabilities[16][20]. - The company has initiated trial production of newly purchased machinery and equipment at the Changchun production base, despite not completing the full expansion by the second quarter of 2024[67]. - The company plans to establish a production base in Dongguan instead of Huizhou due to unexpected delays in obtaining necessary approvals, with the decision to use internal funds for initial investments[68]. - The new production base in Changchun will enhance flexibility to meet the growing demand in Northeast China, where biodegradable product sales accounted for over 80% of the company's revenue[71]. Market and Regulatory Environment - The Chinese government has implemented policies to ban non-biodegradable plastic bags by the end of 2025, which is expected to benefit the company's biodegradable plastic product business[12]. - The Chinese government is expanding the ban on non-biodegradable plastic bags to various commercial venues by the end of 2025, increasing demand for biodegradable products[22][23]. - The company is optimistic about the future prospects of its biodegradable plastic products business, supported by favorable government policies and measures[12]. - The group is strategically positioned to meet the growing demand for biodegradable products due to changing consumer habits and supportive government policies[23]. Research and Development - The group is collaborating with the Changchun Institute of Applied Chemistry for R&D on biodegradable plastic products, enhancing competitive advantages in technology and quality control[19]. - The company plans to enhance its R&D capabilities and upgrade existing R&D equipment, with an allocation of approximately HKD 6.68 million[65]. - The company has a strong focus on research and development in biodegradable products, with key personnel involved in industry associations[82]. - The company is focused on developing smart polymer materials and biodegradable multi-phase materials for biomedical and ecological applications[86]. - The company has published over 50 research papers and holds 15 patents in biodegradable polymers, showcasing its commitment to innovation and research[86]. Governance and Compliance - The company has adopted the corporate governance code as per the Stock Exchange's listing rules for the fiscal year 2024, ensuring compliance with all applicable provisions[93]. - The board of directors consists of four executive directors and several independent non-executive directors, ensuring a diverse and independent governance structure[101]. - The company has established four board committees: Audit Committee, Remuneration Committee, Nomination Committee, and ESG Committee[115]. - The company has adopted a board diversity policy, with a current gender ratio of approximately 0.48:1 among its 161 employees, down from 0.58:1 in 2023[130]. - The company has established a shareholder communication policy to ensure effective communication with shareholders and investors[155]. - The company has implemented a whistleblowing policy to report any suspected violations or misconduct[149]. - The company has adopted a zero-tolerance policy towards bribery, extortion, fraud, and money laundering[148]. - The board has confirmed that the risk management and internal control systems for the fiscal year 2024 are effective and adequate[147]. - The company is committed to transparency and accountability to its shareholders, reinforcing its corporate governance principles[93]. Shareholder Information - The company reported a total issued share capital of HKD 10,000,000, divided into 1,000,000,000 shares with a par value of HKD 0.01 each as of December 31, 2023[159]. - The company has significant shareholdings with Ms. Zhang owning 321,080,700 shares, representing approximately 32.11% of the issued share capital[199]. - Mr. Dan holds 190,822,340 shares, accounting for about 19.08% of the company's issued share capital[199]. - The shareholding structure reflects a concentrated ownership, with the top three shareholders holding over 52% of the total shares[199]. - The report indicates that the company is compliant with the Securities and Futures Ordinance regarding the disclosure of interests[199]. - The company continues to monitor and report on shareholding changes as per regulatory requirements[199]. Employee and Social Responsibility - The total employee cost for the fiscal year 2024 was approximately RMB 14.4 million, an increase from RMB 13.1 million in the previous year[61]. - The company recognizes employees as important assets and provides competitive compensation to attract and retain high-quality staff[165]. - The company made charitable donations of approximately RMB 50,000 in the fiscal year 2024, compared to RMB 30,000 in the fiscal year 2023[176]. - The company has not encountered any significant disputes with customers or suppliers during the fiscal year 2024[166]. - The company has complied with relevant laws and regulations without any serious violations as of the fiscal year 2024[164].

Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 3,407,495 thousand, representing a significant increase from RMB 365,811 thousand in 2023, marking a growth of approximately 831%[4] - Gross profit for the same period was RMB 162,038 thousand, up from RMB 145,454 thousand in 2023, indicating a growth of about 11.5%[4] - The net profit for the year was RMB 112,377 thousand, compared to RMB 84,607 thousand in 2023, reflecting an increase of approximately 32.8%[4] - The total comprehensive income for the year was RMB 112,232 thousand, compared to RMB 90,923 thousand in 2023, showing a growth of around 23.3%[4] - Basic and diluted earnings per share for the year were RMB 11.12, up from RMB 8.80 in 2023, representing an increase of approximately 26.8%[5] - The pre-tax profit for 2024 was RMB 111,161,000, an increase from RMB 83,970,000 in 2023, representing a growth of approximately 32.5%[35] - The group’s profit for the year was approximately RMB 112.4 million, reflecting a growth of 32.9% compared to RMB 84.6 million in the previous fiscal year[75] Assets and Liabilities - Non-current assets increased from RMB 122,412 thousand in 2023 to RMB 112,479 thousand in 2024, indicating a decrease of about 8.1%[6] - Current assets rose from RMB 445,566 thousand in 2023 to RMB 568,192 thousand in 2024, reflecting an increase of approximately 27.5%[6] - Total liabilities increased from RMB 89,839 thousand in 2023 to RMB 127,100 thousand in 2024, representing a growth of about 41.3%[6] - The company's total equity increased from RMB 448,124 thousand in 2023 to RMB 560,356 thousand in 2024, indicating a growth of approximately 25%[7] - Total assets as of December 31, 2024, were RMB 690,604,000, up from RMB 558,045,000 in 2023, indicating a growth of 23.7%[25] - The total interest-bearing loans as of December 31, 2024, were RMB 72,010,000, an increase from RMB 49,658,000 in 2023, with secured loans at RMB 57,250,000 and unsecured loans at RMB 14,760,000[47] Revenue Segmentation - Total segment revenue for biodegradable plastic products reached RMB 381,163 thousand, while non-biodegradable automotive plastic components generated RMB 26,332 thousand, totaling RMB 407,495 thousand[22] - Segment performance showed a gross profit of RMB 151,216 thousand for biodegradable products and RMB 10,822 thousand for automotive components, leading to a total gross profit of RMB 162,038 thousand[22] - The group’s biodegradable products accounted for approximately 80.4% of total revenue from customers in Northeast China, with sales to other cities in China making up about 19.6%[59] Research and Development - Research and development costs amounted to RMB 26,196 thousand, indicating ongoing investment in innovation[22] - Research and development expenses rose significantly to RMB 26,196,000 in 2024, compared to RMB 17,443,000 in 2023, marking an increase of approximately 50.1%[30] - The group has strengthened production capacity and collaborated with major research institutions to enhance the performance and cost of biodegradable materials[61] Operational Expenses - The company incurred administrative and other operating expenses of RMB 41,820 thousand, impacting overall profitability[22] - Administrative and other operating expenses increased by approximately 3.2% from RMB 40.5 million to RMB 41.8 million, primarily due to an increase in R&D expenses of about RMB 8.8 million[71] - Financial costs decreased by approximately 17.5% from RMB 4.0 million to RMB 3.3 million, mainly due to a reduction in bank loan interest and lease liability interest[72] Market Strategy and Expansion - The company is focused on expanding its market presence through the development of biodegradable products, aligning with global sustainability trends[18] - The company plans to continue expanding its market presence in China, where nearly all assets and liabilities are located[26] - The company plans to establish a new production base in Changchun, Jilin Province, to enhance production capacity for biodegradable plastic products, with the project currently in the planning stage[57] - The company has initiated trial production for newly purchased machinery and equipment at the Changchun production base, despite not completing the full expansion by Q2 2024[95] Government Support and Regulations - The company received government subsidies totaling RMB 9,803,000 in 2024, significantly higher than RMB 2,889,000 in 2023[29] - The Chinese government has implemented regulations banning non-biodegradable plastic products, which is expected to increase demand for biodegradable plastic products[63] Corporate Governance - The company has adopted new and revised International Financial Reporting Standards, which are expected to enhance the consistency of financial reporting[11] - The company has adopted the corporate governance code as stipulated in the listing rules and believes it has complied with all applicable provisions during the year[114] - The Audit Committee has reviewed the financial performance for the fiscal year 2024, with no disagreements between the Board and the Audit Committee[119] Shareholder Information - The company did not recommend any dividend for the year ending December 31, 2024, consistent with the previous year[37] - The company will hold its 2025 Annual General Meeting on June 27, 2025, with a suspension of share transfer registration from June 24 to June 27, 2025[118]